Editor's Note: The 2024 European Society for Medical Oncology (ESMO) Congress took place from September 13 to 17 in Barcelona, Spain. As an annual highlight in the oncology field, ESMO attracts thousands of leading oncologists from around the world, providing a rich platform for global academic exchange. This year, multiple studies from Dr. Dingwei Ye’s team at Fudan University Shanghai Cancer Center were selected for presentation at ESMO. Among them, Professor Ye led the study on "BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC)," which received significant attention and discussions, showcasing Chinese expertise and innovation in urologic oncology on a global scale. Urology Frontier had the pleasure of inviting Professor Ye to share his insights on these landmark studies.

Oral Presentation

Abstract No.: 1959O

English Title: BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC)

First Author: Dr. Dingwei Ye, Fudan University Shanghai Cancer Center

Posters

01

Abstract No.: 1649P

English Title: Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial

First Author: Dr. Dingwei Ye, Fudan University Shanghai Cancer Center

02

Abstract No.: 1998P

English Title: Preliminary results from a phase I study of T3011, an oncolytic HSV expressing IL-12 and anti-PD-1 antibody, for BCG-failure non-muscle-invasive bladder cancer (NMIBC)

First Author: Dr. Dingwei Ye, Fudan University Shanghai Cancer Center

03

Abstract No.: 1625P

English Title: Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study

First Author: Professor Yao Zhu, Fudan University Shanghai Cancer Center

04

Abstract No.: 1634P

English Title: Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS

First Author: Dr. Xudong Ni, Fudan University Shanghai Cancer Center

05

Abstract No.: 1640P

English Title: Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients

First Author: Dr. Ziyun Wang, Fudan University Shanghai Cancer Center

Dr. Dingwei Ye

Vice President of Fudan University Shanghai Cancer Center, Chief Expert of Urological Tumor MDT

Director of Shanghai Urological Tumor Research Institute

Director of Fudan University Prostate Cancer Research Institute

Director of the Male Reproductive System Tumor Committee of the Chinese Anti-Cancer Association (CACA-GO)

Director of the Prostate Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO)

Director of the Urology Committee of the China Primary Health Care Foundation Former Director of the Urological Male Reproductive System Tumor Committee of the Chinese Anti-Cancer Association (CACA-GU)

Deputy Director of the Oncology Group of the Urology Branch of the Chinese Medical Association (CUA), Director of CPCC

Deputy Director of the Urothelial Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO)

Deputy Director of the Renal Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO)

Deputy Director of the Immunotherapy Expert Committee of the Chinese Society of Clinical Oncology (CSCO)

Director of the Urological Tumor Collaborative Group of Chinese Tumor Hospitals (UCOG)

Executive Director of the Chinese Anti-Cancer Association, Executive Director of the Chinese Society of Clinical Oncology

Deputy Editor-in-Chief of the Chinese Journal of Oncology Member of the NCCN Prostate Cancer, Renal Cancer, Bladder Cancer Asian Consensus Expert Committee

Member of the Advanced Prostate Cancer St. Gallen Consensus Expert Committee

Director of the Urological Tumor Committee of the Shanghai Anti-Cancer Association

Vice President of the Urology Physician Branch of the Shanghai Medical Association

Immediate Past President of the Asia-Pacific Prostate Society (APPS) Vice President of the Asia-Pacific Society for Cryosurgery